Company description

United Therapeutics Corporation (UTHR) is a biotechnology company that focuses on the development and commercialization of unique medicines to treat serious medical conditions. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. UTHR specializes in the treatment of pulmonary hypertension, a rare disease that affects the blood vessels in the lungs and can be life-threatening. The company also has a diverse portfolio of products that target other conditions such as neuroblastoma, hepatocellular carcinoma, and infectious diseases. UTHR has a strong track record of success in bringing innovative and life-saving drugs to market. Its flagship product is Remodulin, a treatment for pulmonary arterial hypertension, which has been approved by the FDA for over 15 years. The company also has other leading products in its pipeline, including Orenitram and Tyvaso, which are also used to treat pulmonary hypertension. In addition to its current product portfolio, UTHR is actively involved in ongoing research and development efforts to bring new and improved treatments to patients in need. One of the key factors that sets UTHR apart from other biotechnology companies is its commitment to patient advocacy. The company works closely with patient support groups and organizations to raise awareness about pulmonary hypertension and to provide resources for those affected by the disease. UTHR also offers financial assistance programs to help patients access its medications, making them more affordable and accessible. With a strong financial performance and a dedicated team of scientists, researchers, and industry experts, UTHR